Tuesday, July 30, 2024 2:58:39 PM
FeMike,
The dilution is currently and obviously a big part of the equation and without any positive news from the judges decision on motion to dismiss or approval news the absence of news creates the current trend.
At some point management should make a move to support the price collectively since individual moves have basically no effect. A symbolic buy or loan with favorable terms to all shareholders covered by warrants at a much higher strike price and one year expiration would be a good way to do this. Of course they are under no obligation to do this which would create a surprise likely greeted with increased investor support in the short term and longer term if tangible management support continues. Some who have been looking for a change in ongoing management actions would see this as very positive IF there is follow through which makes now just about right for best timing with great expectations coming over the next 17 months. Best wishes.
The dilution is currently and obviously a big part of the equation and without any positive news from the judges decision on motion to dismiss or approval news the absence of news creates the current trend.
At some point management should make a move to support the price collectively since individual moves have basically no effect. A symbolic buy or loan with favorable terms to all shareholders covered by warrants at a much higher strike price and one year expiration would be a good way to do this. Of course they are under no obligation to do this which would create a surprise likely greeted with increased investor support in the short term and longer term if tangible management support continues. Some who have been looking for a change in ongoing management actions would see this as very positive IF there is follow through which makes now just about right for best timing with great expectations coming over the next 17 months. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
